It is likely that more aggressive tumor subclones overcome the treatment, mostly owing to secondary, resistant KIT mutations, and these remaining cells after TKI treatment might be sufficient for further tumor growth in the laboratory mice (Liegl et al., 2008). Here, KIT is linked to neoplasm.